Eliglustat (Cerdelga) is indicated for the long-term treatment of adult patients with Gaucher disease type 1 (GD1) who are poor metabolizers, intermediate metabolizers, or extensive metabolizers of the enzyme cytochrome P450 2D6 (CYP2D6). The dosage is 84 mg once daily in CYP2D6 poor metabolizers, and 84 mg twice daily in CYP2D6 intermediate and extensive metabolizers. It is administered orally. The submitted price of eliglustat is $695 per capsule ($253,675 or $507,350 annually).

The manufacturer submitted a cost-utility analysis comparing eliglustat with two enzyme replacement therapies (ERTs), imiglucerase and velaglucerase, in treatment-naive and treatment-stable adult patients with GD1 over a lifetime time horizon (up to 100 years). The cost-utility analysis is from the perspective of the Canadian public health care payer. The manufacturer assumed equivalence between eliglustat and the ERTs based on a review of available clinical trial data. The same transition probabilities for eliglustat and the ERTs for health states were adopted from the ENGAGE and ENCORE studies (short-term) and a retrospective cohort study (long-term). Data from manufacturer-commissioned reports and the published studies of eliglustat, imiglucerase, and velaglucerase were used to determine the discontinuation and adverse event rates applied in the model. Other inputs such as costs and utility values were obtained from published literature.

In its base case, the manufacturer reported that eliglustat dominated (was more effective and less costly than) imiglucerase or velaglucerase. In a probabilistic sensitivity analysis of 50 simulations, at a willingness-to-pay threshold of $50,000 per qualityadjusted life-year (QALY), imiglucerase or velaglucerase were preferred treatment strategies in approximately 40% of simulations.

Contents

• Abbreviations
• Executive Summary
• Information on the Pharmacoeconomic Submission
  • Summary of the Manufacturer’s Pharmacoeconomic Submission
  • Manufacturer’s Base Case
  • Summary of Manufacturer’s Sensitivity Analyses
  • Limitations of Manufacturer’s Submission
  • CADTH Common Drug Review Reanalyses
  • Issues for Consideration
  • Patient Input
  • Conclusions
• Appendix 1. Cost Comparison
• Appendix 2. Summary of Key Outcomes
• Appendix 3. Additional Information
• Appendix 4. Summary of Other Health Technology Assessment Reviews of Drug
• Appendix 5. Reviewer Worksheets
• References

Version: 1.0

Disclaimer: The information in this document is intended to help Canadian health care decision-makers, health care professionals, health systems leaders, and policy-makers make well-informed decisions and thereby improve the quality of health care services. While patients and others may access this document, the document is made available for informational purposes only and no representations or warranties are made with respect to its fitness for any particular purpose. The information in this document should not be used as a substitute for professional medical advice or as a substitute for the application of clinical judgment in respect of the care of a particular patient or other professional judgment in any decision-making process. The Canadian Agency for Drugs and Technologies in Health (CADTH) does not endorse any information, drugs, therapies, treatments, products, processes, or services.

While care has been taken to ensure that the information prepared by CADTH in this document is accurate, complete, and up-to-date as at the applicable date the material was first published by CADTH, CADTH does not make any guarantees to that effect. CADTH does not guarantee and is not responsible for the quality, currency, propriety, accuracy, or reasonableness of any statements, information, or conclusions contained in any third-party materials used in preparing this document. The views and opinions of third parties published in this document do not necessarily state or reflect those of CADTH.

CADTH is not responsible for any errors, omissions, injury, loss, or damage arising from or relating to the use (or misuse) of any information, statements, or conclusions contained in or implied by the contents of this document or any of the source materials.

This document may contain links to third-party websites. CADTH does not have control over the content of such sites. Use of third-party sites is governed by the third-party website owners’ own terms and conditions set out for such sites. CADTH does not make any guarantee with respect to any information contained on such third-party sites and CADTH is not responsible for any injury, loss, or damage suffered as a result of using such third-party sites. CADTH has no responsibility for the collection, use, and disclosure of personal information by third-party sites.

Subject to the aforementioned limitations, the views expressed herein are those of CADTH and do not necessarily represent the views of Canada’s federal, provincial, or territorial governments or any third party supplier of information.

This document is prepared and intended for use in the context of the Canadian health care system. The use of this document outside of Canada is done so at the user’s own risk.

This disclaimer and any questions or matters of any nature arising from or relating to the content or use (or misuse) of this document will be governed by and interpreted in accordance with the laws of the Province of Ontario and the laws of Canada applicable therein, and all proceedings shall be subject to the exclusive jurisdiction of the courts of the Province of Ontario, Canada.

The statements, findings, conclusions, views, and opinions contained and expressed in this publication are based in part on data obtained under license from QuintilesIMS concerning the following information service: DeltaPA. All Rights Reserved. Subject to the aforementioned limitations, the views expressed herein are those of CADTH and do not necessarily represent the views of Canada’s federal, provincial, or territorial governments or any third-party data supplier